We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SSKN
226
DELISTED
Strata Skin Sciences
SSKN
$128K ﹤0.01%
1,484
-5,092
-77% -$597K
WINT
227
DELISTED
Windtree Therapeutics Inc
WINT
$120K ﹤0.01%
4,643
-17,904
-79% -$432K
ECYT
228
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$97K ﹤0.01%
159
-1,001
-86% -$6.84K
CRDF icon
229
Cardiff Oncology
CRDF
$111M
$92K ﹤0.01%
278
– –
ATHX
230
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$90K ﹤0.01%
26
+19
+271% +$728
GNMX
231
PUT
DELISTED
Aevi Genomic Medicine Inc
GNMX
$75K ﹤0.01%
+145
New +$936
OXGN
232
CALL
DELISTED
OXIGENE INC COM
OXGN
$74K ﹤0.01%
344
+69
+25% +$160
INFI
233
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$73K ﹤0.01%
+5,438
New +$64.8K
ECYT
234
DELISTED
Endocyte, Inc. Common Stock
ECYT
$69K ﹤0.01%
+11,300
New +$77.2K
GERN icon
235
PUT
Geron
GERN
$848M
$65K ﹤0.01%
107
-6
-5% -$15
LSTA icon
236
Lisata Therapeutics
LSTA
$13.3M
$63K ﹤0.01%
76
-478
-86% -$418K
NBSE
237
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$62K ﹤0.01%
2
– –
CTIC
238
PUT
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$62K ﹤0.01%
+26
New +$676
FOCL
239
CALL
EDAP TMS S.A.
FOCL
$190M
$55K ﹤0.01%
423
-323
-43% -$883
OXGN
240
PUT
DELISTED
OXIGENE INC COM
OXGN
$48K ﹤0.01%
+222
New +$515
CASC
241
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$32K ﹤0.01%
28
-11
-28% -$168
ALBO
242
PUT
DELISTED
Albireo Pharma Inc
ALBO
$30K ﹤0.01%
6
– –
CGEN icon
243
Compugen
CGEN
$228M
$29K ﹤0.01%
+3,400
New +$30.2K
SEEL
244
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
AZN icon
245
AstraZeneca
AZN
$252B
$21K ﹤0.01%
215,323
+159,048
+283% +$11.6M
IMUC
246
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$21K ﹤0.01%
6
+1
+20% +$39
FOCL
247
EDAP TMS S.A.
FOCL
$190M
$19K ﹤0.01%
+14,524
New +$39.7K
FOCL
248
PUT
EDAP TMS S.A.
FOCL
$190M
$18K ﹤0.01%
139
-187
-57% -$511
CVM icon
249
CEL-SCI Corp
CVM
$26M
$12K ﹤0.01%
17
– –
ABBV icon
250
PUT
AbbVie
ABBV
$459B
– –
-2,712
Closed -$15.3M
8 9
10
11 12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.